A study of mustadi kwatha and vangeshwara rasa in the management of madhumeha (Type 2 Diabetes mellitus)

A randomized comparative clinical study to evaluate the efficacy of mustadi kwatha and vangeshwara rasa in the management of madhumeha w.s.r. to type 2 Diabetes mellitus.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/09/015869

Enrollment

Registered

2018-09-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications Health Condition 2: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Group A: In this group 15 patients will be administered trial drug mustadi kwatha orally in the dose of 50 ml twice a day before meals for 45 days. Intervention2: Group B: In this group

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient willing to sign the consent form. 2. Patients in the age group of 30-70 years. 3. Patients with Fasting Blood Sugar (FBS) in the range of 126mg/dl â?? 250mg/dl or Post Prandial Blood Sugar (PPBS) in the range of 200mg/dl â?? 300 mg/dl and Glycosylated Haemoglobin (HbA1c) 6.5% - 9.0% .

Exclusion criteria

Exclusion criteria: 1. Patients below 30 years & above 70 years of age. 2. Patients having Type 1 DM. 3. Patients of Type 2 DM who are on insulin therapy. 4. Patients having any serious illness like coronary artery disease, malignancy, kidney failure etc. 5. Patient whose Fasting Blood Sugar (FBS) > 250 mg/dl or Post Prandial Blood Sugar (PPBS) > 300 mg/dl or Glycosylated Haemoglobin (HbA1c) > 9.0%. 6. DM with complications. 7. Pregnant women and lactating mother.

Design outcomes

Primary

Measure	Time frame
Assessment of changes in Blood Sugar Level (FBS,PPBS) and specific signs and symptoms of Madhumeha (Type 2 Diabetes Mellitus)Timepoint: 45 days	—

Secondary

Measure	Time frame
Any adverse effect in the values of hematological test and in clinical signs and symptoms.Timepoint: 45 days	—

Countries

India

Contacts

Public ContactDr Hari Khanal

National Institute of Ayurveda

joshirk1964@gmail.com9414322297

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026